American Medical Association

Sequana Medical announces 2023 Full Year Results and 2024 Outlook

Retrieved on: 
Thursday, March 28, 2024
Cardiorenal syndrome, Cirrhosis, Partner, Congestion, American Medical Association, Ascites, DSR, Brussels Stock Exchange, Liver disease, RED, Patient, Peritoneal dialysis, 2.0, Mouse, Sheep, Cancer, Heart, Heart failure, PMA, US FDA, Safety, File, CPT9, Overload, Catheter, ISO, THT, FDA, Animal, Pharmaceutical industry

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.
  • Furthermore, the alfapump can benefit from attractive pricing and leverage its FDA breakthrough device designation to enhance its reimbursement position.
  • Following this equity placement, the €3.0 million convertible loan agreement entered in February 2024 by Partners in Equity and Rosetta Capital will be mandatorily converted into new shares.
  • A day-100 meeting is scheduled with the FDA on April 9th 2024.

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Retrieved on: 
Monday, April 8, 2024
Research, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, JAMA, American Medical Association, Cardiovascular disease, Serum, Patient, Journal, RNA, MD, Therapy, Moyamoya disease, Safety, Small RNA, APOLLO, ASCVD, Pharmaceutical industry

“Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.

Key Points: 
  • “Positive phase 1 data published in JAMA demonstrate treatment with zerlasiran produced sustained reductions in Lp(a) concentrations with a well-tolerated profile using varying dosing regimens,” said Curtis Rambaran, MD, Chief Medical Officer at Silence and senior author of the publication.
  • Results from the single ascending dose portion of the trial in healthy participants were previously published in the April 2022 issue of JAMA, linked here .
  • Secondary outcomes included the serum levels of zerlasiran and effects on Lp(a) serum concentrations.
  • Zerlasiran is currently being evaluated in the ALPACAR-360 phase 2 study in subjects with baseline Lp(a) levels at or over 125 nmol/L at high risk of ASCVD events.

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

Retrieved on: 
Wednesday, March 20, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, JAMA, Lewy body, Diagnosis, Harvard Medical School, American Medical Association, DLB, MSA, Disease, PD, Multiple system atrophy, Alpha-synuclein, Physician, Journal, CND, MD, NIH, Synucleinopathy, Skin, Pathology, Bangladesh Technical Education Board, Medicare, PAF, Dementia, Phosphorylation, Medical imaging

The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.

Key Points: 
  • The primary goal of this study was to define the positivity rate of skin biopsies to detect P-SYN deposition in clinically confirmed cases of PD, MSA, DLB, and PAF.
  • The proportion of patients with P-SYN was 92.7% in those with PD, 98.2% in those with MSA, 96.0% in those with DLB, and 100% in those with PAF.
  • Future disease-modifying therapies will require convenient, accurate, and precise diagnostic tools to reach the right patients at the right time across a wide array of communities.
  • “The publication of this important NIH-sponsored study is one big step forward with many more milestones to come.”

ICPO ACADEMY FOR THERANOSTICS to Grant EACCME Credits after Accreditation by Union Européenne des Médecins Spécialistes (UEMS)

Retrieved on: 
Wednesday, March 20, 2024
Research, Other Health, Radiology, Philanthropy, Oncology, Continuing, Hospitals, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, Pillar, Medical physics, Union, American Medical Association, ICPO, Radiochemistry, Patient, Accreditation, Nursing, News, Cancer, Quality of life, Continuing medical education, CME, Licensure, Curriculum, Safety, Multimedia, Physician

We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.

Key Points: 
  • We are thrilled to announce the prestigious accreditation form the Union Européenne des Médecins Spécialistes (UEMS), an esteemed institution dedicated to enhancing medical education and professional standards across Europe.
  • Odile Jaume, CEO of the ICPO Foundation, commented on the news of UEMS: "The accreditation from UEMS is a significant milestone for the ICPO ACADEMY FOR THERANOSTICS.
  • The ICPO ACADEMY FOR THERANOSTICS offers a comprehensive online educational program, developed by the ICPO Foundation and powered by its global community of experts.
  • For one of these pillars, participants of the ICPO ACADEMY FOR THERANOSTICS receives 10 credits for their educational training.

Hamline University Research Validates Highly Cost-Effective Impairment Assessment Algorithm for Workers' Compensation Cases

Retrieved on: 
Wednesday, April 3, 2024
Physics, NP-hardness, Health, American Medical Association, Headache, Patient, FLR, Research, Table, Doctor of Philosophy, MD, Insurance, ADL, Lawyer, FCR, Heart, WPI, QME, Fifth Edition, Hamline University, Nursing

ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases. The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based. The study demonstrates that the computational FLR method is consistently more accurate than the traditional, manual Four Corners Rating (FCR) system, the current industry standard for WPI measurement.

Key Points: 
  • ST. PAUL, Minn., April 3, 2024 /PRNewswire-PRWeb/ -- Hamline University, in collaboration with impairment rating calculations company Rate-Fast, today announced groundbreaking research that revolutionizes the assessment of impairment in workers' compensation cases.
  • The study validates a novel algorithm-based Functional Loss Rating (FLR) method, which offers a more objective, efficient, and cost-effective approach for calculating a whole-person impairment (WPI) score, upon which compensation for work-related injuries is based.
  • FLR is a mathematical impairment evaluation method that uses advanced data analytics to calculate an objective, accurate WPI rating.
  • The algorithm at the heart of FLR was built on more than a decade of research comprised of nearly 70,000 impairment case rating experiences.

The Association for Diagnostics & Laboratory Medicine (formerly AACC) recommends to Congress that the regulation and modernization of clinical tests be managed under the auspices of the Clinical Laboratory Improvement Advisory Committee, CMS, and Congress

Retrieved on: 
Tuesday, April 2, 2024
American Medical Association, Education, Congress, Labour, Ranking, Committee, AACC, Communication, Diagnosis, Children's Hospital Association, CLIA, Clinical Laboratory, Medical laboratory, Medicare, FDA, CMS, Health, Food, Medical device

Specifically, ADLM supports modernizing the Clinical Laboratory Improvement Amendments (CLIA), through which the Centers for Medicare & Medicaid Services (CMS) regulates laboratory developed tests.

Key Points: 
  • Specifically, ADLM supports modernizing the Clinical Laboratory Improvement Amendments (CLIA), through which the Centers for Medicare & Medicaid Services (CMS) regulates laboratory developed tests.
  • Additional FDA oversight would be duplicative, costly — and could force many clinical labs to stop performing these essential tests.
  • "As an alternative, ADLM suggests updating CLIA's standards through the Clinical Laboratory Improvement Advisory Committee (CLIAC).
  • "Once changes are made through the regulatory process, ADLM proposes that Congress evaluate and update the underlying statute that governs CLIA.

The Inner Circle acknowledges Antony Jackson Arumairaj, MD as a Top Pinnacle Physician

Retrieved on: 
Tuesday, April 2, 2024
College, Research, American Medical Association, Royal Australasian College, Internal medicine, Critical Care Medicine (journal), Patient, Publishing, Emergency medicine, MD, American College of Physicians, Mentorship, Royal college, American Thoracic Society, Society, Bachelor, American College, Stanley Medical College, Internship, Multimedia, Health, Inner circle, Teaching, Nursing

JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.

Key Points: 
  • JERSEY CITY, N.J., April 2, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Antony Jackson Arumairaj, MD is acknowledged as a Top Pinnacle Physician for his contributions as a Distinguished Internal Medicine Specialist.
  • In this capacity, he not only provides exceptional patient care but also plays a pivotal role in teaching and mentoring medical students.
  • His dedication to the well-being of his patients and commitment to medical education make him a valuable asset to the healthcare community.
  • He aims to complete his Pulmonary Critical Care fellowship and become an Attending Physician at a university hospital.

Syra Health Secures Statewide Healthcare Contract in Missouri

Retrieved on: 
Thursday, March 28, 2024
American Medical Association, Growth, Physician, Nursing

CARMEL, Ind., March 28, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today it has secured a healthcare workforce contract in Missouri for providing temporary medical services personnel. Revenue from the contract will be determined based on the number of positions filled and their duration.

Key Points: 
  • CARMEL, Ind., March 28, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today it has secured a healthcare workforce contract in Missouri for providing temporary medical services personnel.
  • The contract encompasses the recruitment of specialized medical professionals crucial to addressing healthcare needs across Missouri.
  • Dr. Deepika Vuppalanchi, CEO, Syra Health, underscored the significance of winning this statewide contract, stating, "We are thrilled to expand our operations into Missouri and further our goal of enhancing healthcare delivery across the nation.
  • Today's contract marks the 18th state where Syra Health has established a presence, reinforcing its commitment to delivering quality healthcare solutions nationwide.

CENTEGIX® Launches Healthcare Safety Platform™ to Protect Frontline Workers

Retrieved on: 
Wednesday, March 27, 2024
Emergency, American Medical Association, Job satisfaction, Public health, Commissioner, Safety, School, SVP, Hospital, Health care, Magic, Emergency Nurses Association, Baystate Health, Former, Emergency medicine, Tufts Medical Center, American Osteopathic Association, Workplace, Nursing, ENA, Workplace violence, Commonwealth, Violence

ATLANTA, March 27, 2024 /PRNewswire/ -- CENTEGIX, the leading wearable safety technology provider, announces the launch of its CENTEGIX Safety Platform™ for hospitals and health systems, a cloud-based integrated solution designed to initiate the fastest response time to safety incidents across any hospital campus.

Key Points: 
  • Healthcare workers are some of the most threatened in the workplace as violence against healthcare staff continues to rise.
  • "The healthcare workers who protect us are among the most threatened in their workplace," said Brent Cobb, CEO of CENTEGIX.
  • The design of the Safety Platform is based on CENTEGIX's experience supporting frontline workers in various industries, predominantly K-12 educators, who also experience workplace safety concerns.
  • There isn't a magic fix-all for workplace violence in the healthcare setting, but with proactive and multi-layered safety plans, we can make improvements to better protect our healthcare staff.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.